{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T20:03:45Z","timestamp":1789329825560,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T00:00:00Z","timestamp":1789257600000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clinthera.2026.08.004","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:45:27Z","timestamp":1788950727000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Finerenone-Based Dual Versus Triple Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus Associated Chronic Kidney Disease: A Retrospective Cohort Study"],"prefix":"10.1016","author":[{"given":"Mohammed","family":"Khogalee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0187-9056","authenticated-orcid":false,"given":"Sami","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Otim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momna","family":"Basher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madiha","family":"Mumtaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaza","family":"Thaslim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"El Houni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2026.08.004_bib0001","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s43088-023-00428-y","article-title":"The rising burden of chronic kidney diseases in patients with diabetes","volume":"12","author":"Almomani","year":"2023","journal-title":"Beni-Suef Univ J Basic Appl Sci"},{"key":"10.1016\/j.clinthera.2026.08.004_bib0002","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.2337\/dc23-S011","article-title":"11. Chronic Kidney Disease and Risk Management: standards of Care in Diabetes\u20142023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2026.08.004_bib0003","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1080\/14656566.2021.1904892","article-title":"Finerenone \u2013 are we there yet with a non-steroidal mineralocorticoid receptor antagonist for the treatment of diabetic chronic kidney disease?","volume":"22","author":"Doggrell","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinthera.2026.08.004_bib0005","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.08.004_bib0006","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.08.004_bib0007","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/17512433.2022.2094770","article-title":"Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes","volume":"15","author":"Lerma","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2026.08.004_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.metop.2024.100318","article-title":"Efficacy and safety of finerenone in individuals with type 2 diabetes mellitus complicated by diabetic kidney disease: a retrospective observational study","volume":"24","author":"Kawaguchi","year":"2024","journal-title":"Metab Open"},{"key":"10.1016\/j.clinthera.2026.08.004_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.metop.2023.100251","article-title":"Effect of finerenone on diabetic kidney disease outcomes with estimated glomerular filtration rate below 25 mL\/min\/1.73 m2","volume":"19","author":"Mima","year":"2023","journal-title":"Metab Open"},{"key":"10.1016\/j.clinthera.2026.08.004_bib0010","doi-asserted-by":"crossref","first-page":"198","DOI":"10.4103\/ijem.ijem_376_21","article-title":"Efficacy and Safety of Novel Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in the Management of Diabetic Kidney Disease: a Meta-analysis","volume":"26","author":"Dutta","year":"2022","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2026.08.004_bib0011","unstructured":"Technology appraisal guidance Reference. Finerenone for treating chronic kidney disease in type 2 diabetes. https:\/\/www.nice.org.uk\/guidance\/ta877. Accessed January 15, 2026."},{"key":"10.1016\/j.clinthera.2026.08.004_bib0012","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.2337\/dc23-S010","article-title":"10. Cardiovascular disease and risk management: standards of care in diabetes\u20142023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2026.08.004_bib0013","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinthera.2026.08.004_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115661","article-title":"Finerenone protects against progression of kidney and cardiovascular damage in a model of type 1 diabetes through modulation of proinflammatory and osteogenic factors","volume":"168","author":"Sanz-G\u00f3mez","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.clinthera.2026.08.004_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112050","article-title":"A critical review on SGLT2 inhibitors for diabetes mellitus, renal health, and cardiovascular conditions","volume":"221","author":"Kumar","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.clinthera.2026.08.004_bib0016","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.tcm.2024.03.003","article-title":"The cardiovascular effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: an anti-atherosclerotic action","volume":"34","author":"Alexiadou","year":"2024","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.clinthera.2026.08.004_bib0017","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000040364","article-title":"Effect of GLP-1 receptor agonists on weight and cardiovascular outcomes: a review","volume":"103","author":"Raza","year":"2024","journal-title":"Medicine"},{"key":"10.1016\/j.clinthera.2026.08.004_bib0018","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.08.004_bib0019","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfaf051","article-title":"SGLT2 inhibitors in CKD: are they really effective in all patients?","author":"Romagnani","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clinthera.2026.08.004_bib0020","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","article-title":"Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy","volume":"7","author":"Rossing","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.clinthera.2026.08.004_bib0021","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12933-022-01676-5","article-title":"Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"21","author":"Zhang","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.clinthera.2026.08.004_bib0022","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/dom.14883","article-title":"Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use","volume":"25","author":"Rossing","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2026.08.004_bib0023","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1093\/ndt\/gfac046","article-title":"SGLT2 inhibitors and finerenone: one or the other or both?","volume":"37","author":"Neuen","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clinthera.2026.08.004_bib0024","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"Elm","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2026.08.004_bib0025","unstructured":"STROBE checklist: cohort studies. \u200bhttps:\/\/www.strobe-statement.org\/download\/strobe-checklist-cohort-studies-doc. Accessed January 15, 2026."},{"key":"10.1016\/j.clinthera.2026.08.004_bib0026","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s13098-024-01497-4","article-title":"Effects of glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in high-risk type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"16","author":"Chen","year":"2024","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.clinthera.2026.08.004_bib0027","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2026.08.004_bib0028","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.2337\/dc25-1673","article-title":"Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial)","volume":"48","author":"Agarwal","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2026.08.004_bib0029","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2026.08.004_bib0030","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1186\/s12933-025-02900-8","article-title":"Cardiovascular and renal outcomes of dual combination therapies with glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors: a systematic review and meta-analysis","volume":"24","author":"Shokravi","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.clinthera.2026.08.004_bib0031","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078242","article-title":"Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study","author":"Simms-Williams","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2026.08.004_bib0032","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.08.004_bib0033","doi-asserted-by":"crossref","first-page":"4140","DOI":"10.1111\/bcp.14855","article-title":"Impact of glucagon-like peptide-1 receptor agonists on adiponectin concentrations: a meta-analysis of randomized controlled trials","volume":"87","author":"Simental-Mend\u00eda","year":"2021","journal-title":"Brit J Clin Pharma"},{"key":"10.1016\/j.clinthera.2026.08.004_bib0034","doi-asserted-by":"crossref","first-page":"602","DOI":"10.2337\/dc22-1514","article-title":"Efficacy of dapagliflozin by baseline diabetes medications: a prespecified analysis from the DAPA-CKD study","volume":"46","author":"Beernink","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2026.08.004_bib0035","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Group","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.08.004_bib0036","first-page":"gfaf064","article-title":"Cardio-kidney outcomes for combined versus monotherapy with finerenone or SGLT2 inhibitors in patients with CKD","author":"Chuang","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clinthera.2026.08.004_bib0037","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1053\/j.ajkd.2021.02.335","article-title":"Changes in GFR and albuminuria in routine clinical practice and the risk of kidney disease progression","volume":"78","author":"Neuen","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clinthera.2026.08.004_bib0038","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.033236","article-title":"Initial eGFR changes with SGLT2 inhibitor in patients with type 2 diabetes and associations with the risk of abnormal serum potassium level","volume":"13","author":"Kao","year":"2024","journal-title":"JAHA"},{"key":"10.1016\/j.clinthera.2026.08.004_bib0039","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejim.2023.05.038","article-title":"Efficacy and safety assessment of mineralocorticoid receptor antagonists in patients with chronic kidney disease","volume":"115","author":"Ding","year":"2023","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.clinthera.2026.08.004_bib0040","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial","volume":"33","author":"Agarwal","year":"2022","journal-title":"JASN"},{"key":"10.1016\/j.clinthera.2026.08.004_bib0041","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078483","article-title":"SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study","author":"Fu","year":"2024","journal-title":"BMJ"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182600305X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182600305X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T19:34:57Z","timestamp":1789328097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929182600305X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":40,"alternative-id":["S014929182600305X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.08.004","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Finerenone-Based Dual Versus Triple Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus Associated Chronic Kidney Disease: A Retrospective Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}